ReviewImmunologic research2011
T cell recognition of weak ligands: roles of signaling, receptor number, and affinity.
Review in Immunologic research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Characterization of the UK anthrax vaccine and human immunogenicity.Human vaccines & immunotherapeutics · 2021Article
- Immune Autoregulatory CD8 T Cells Require IFN-γ Responsiveness to Optimally Suppress Central Nervous System Autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Dual TCR T Cells: Identity Crisis or Multitaskers?Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- CTL-Derived Exosomes Enhance the Activation of CTLs Stimulated by Low-Affinity Peptides.Frontiers in immunology · 2019Article
- CD4AIDS research and human retroviruses · 2018Review
- Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.Frontiers in immunology · 2018Review
- Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.Frontiers in immunology · 2018Review
- Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms.Immunogenetics · 2017Review
- Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses.Vaccine · 2016Article
- Expressing Redundancy among Linear-Epitope Sequence Data Based on Residue-Level Physicochemical Similarity in the Context of Antigenic Cross-Reaction.Advances in bioinformatics · 2016Article
- Cutting edge: The signals for the generation of T cell memory are qualitatively different depending on TCR ligand strength.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- The basic principles of chimeric antigen receptor design.Cancer discovery · 2013Review
- Primer on tumor immunology and cancer immunotherapy.Journal for immunotherapy of cancer · 2013Review
- Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity.PloS one · 2013Article
- Host and microbial factors in regulation of T cells in the intestine.Frontiers in immunology · 2013Article
- Article
- Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes.Genes & cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
T cell recognition of antigen is a crucial aspect of the adaptive immune response. One of the most common means of pathogen immune evasion is mutation of T cell epitopes. T cell recognition of such ligands can result in a variety of outcomes including activation, apoptosis and anergy. The ability of a given T cell to respond to a specific peptide-MHC ligand is regulated by a number of factors, including the affinity, on- and off-rates and half-life of the TCR-peptide-MHC interaction. Interaction of T cells with low-potency ligands results in unique signaling patterns and requires engagement with a larger number of T cell receptors than agonist ligands. This review will address these aspects of T cell interaction with weak ligands and the ways in which these ligands have been utilized therapeutically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.